Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
COVID-19
Hematopoietic stem cell transplantation
Immune response
SARS-CoV-2
mRNA vaccine
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
18 03 2022
18 03 2022
Historique:
received:
17
01
2022
accepted:
07
03
2022
entrez:
19
3
2022
pubmed:
20
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died.
Identifiants
pubmed: 35303906
doi: 10.1186/s13045-022-01250-2
pii: 10.1186/s13045-022-01250-2
pmc: PMC8931584
doi:
Substances chimiques
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Informations de copyright
© 2022. The Author(s).
Références
J Clin Microbiol. 2022 Jan 19;60(1):e0174621
pubmed: 34705539
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Hematol Oncol. 2021 Oct 24;14(1):174
pubmed: 34689821
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Blood. 2022 Mar 10;139(10):1439-1451
pubmed: 34662390
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Leukemia. 2021 Oct;35(10):2885-2894
pubmed: 34079042
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet Haematol. 2021 Oct;8(10):e681-e683
pubmed: 34487683
Lancet. 2021 Jul 24;398(10297):298-299
pubmed: 34270933
Chest. 2020 Apr;157(4):e99-e101
pubmed: 32087216